Back

Spironolactone in patients with permanent atrial fibrillation, possible heart failure protective potential.

2 September 2019 (08:30 - 12:30)
Organised by:
Congress Presentation Part of: Poster Session 4 - Epidemiology of atrial fibrillation, miscellaneous Mechanisms for Heart Failure and Cardiac Complications ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor Rafal Dabrowski

National Institute of Cardiology, Warsaw (Poland)

9 More presentations in this session

Presentation thumbnail
Associate Professor M. Dzeshka (Grodno, BY)
Abstract Slides
Presentation thumbnail
Doctor H. Kishima (Nishinomiya, JP)
Abstract Slides
Presentation thumbnail
Doctor H. Arshad (Newark, US)
Presentation thumbnail
Doctor J. Graby (Bristol, GB)
Abstract
Presentation thumbnail
Doctor K. Kadhim (Adelaide, AU)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 4 - Epidemiology of atrial fibrillation, miscellaneous

The Event

Event poster

ESC Congress 2019

2 September 2019 08:30 CET
You may be interested in
thumbnail
Congress Presentation
Atrial fibrillation and exercise capacity in patients with and without heart failure during exercise-based cardiac rehabilitation
29 August 2025
thumbnail
Congress Presentation
Adverse effects of spironolactone in long-term treatment of resistant arterial hypertension
1 September 2019
thumbnail
Congress Presentation
The effect of eplerenone on fibrosis in hypertrophic cardiomyopathy. A randomised controlled trial assessed using cardiopulmonary exercise testing and cardiovascular magnetic resonance
1 September 2019
thumbnail
Congress Presentation
Are the results of the RATE-AF trial reproducible in daily practice? Clinical outcomes with digoxin vs beta-blocker for heart rate control in permanent atrial fibrillation
30 August 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources